Upgrade

Finvezto Toolkit

Biocon won European Commission marketing authorisation for Pebrilzo, its biosimilar to Roche's breast cancer drug Perjeta.

Legal · 18 Nov 2026 · Biocon (BIOCON)

It follows US FDA approval two days earlier, so the drug now has clearance in both large markets. Biocon says it is the first biosimilar approved under the EMA's tailored clinical pathway.

Company page

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.